DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 020216/S-073
NDA 020216/S-074
NDA 020216/S-075

SUPPLEMENT APPROVAL

Wyeth Pharmaceuticals, Inc.
c/o Pfizer Inc.
Attention: Ursula Campbell
Senior Director, Worldwide Regulatory Strategy
235 East 42nd Street
New York, NY 10017

Dear Ms. Campbell:

Please refer to your Supplemental New Drug Applications (sNDAs) dated March 11, 2010, for S-073; April 28, 2010, for S-074; and August 20, 2010, for S-075, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for PREMARIN® (conjugated estrogens) Vaginal Cream.

We acknowledge receipt of your amendments dated February 25, August 5, and September 6, 2011.

These "Changes Being Effected" supplemental new drug applications, as amended, provide for the following changes:

- Addition of two new CONTRAINDICATIONS of known anaphylactic reaction or angioedema and known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders
- Addition of two new WARNINGS AND PRECAUTIONS of anaphylactic reaction and angioedema and hereditary angioedema
- Updates to the ADVERSE REACTIONS section to reflect treatment related adverse reactions
- Revisions to selected sections of the Prescribing Information to reflect current recommended estrogen-class labeling
- Revisions to selected sections of FDA-approved Patient Labeling to reflect changes in the Prescribing Information, including the addition of not starting therapy in the presence of a bleeding disorder

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

PROMOTIONAL MATERIALS

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kim Shiley, R.N., B.S.N., Regulatory Project Manager, at (301) 796-2117.

Sincerely,

{See appended electronic signature page}

Christine P. Nguyen, M.D.
Acting Deputy Director for Safety
Division of Reproductive and Urologic Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

CHRISTINE P NGUYEN
02/14/2012